[
  {
    "ts": null,
    "headline": "These Institutional Investors Are Raising Their Stakes in Johnson & Johnson Stock. Should You Do the Same?",
    "summary": "They might be on to something.",
    "url": "https://finnhub.io/api/news?id=130128aedbcbb42898312d198513c7dc118e5853bae5e2b498e3159279257066",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765561800,
      "headline": "These Institutional Investors Are Raising Their Stakes in Johnson & Johnson Stock. Should You Do the Same?",
      "id": 137770377,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "They might be on to something.",
      "url": "https://finnhub.io/api/news?id=130128aedbcbb42898312d198513c7dc118e5853bae5e2b498e3159279257066"
    }
  },
  {
    "ts": null,
    "headline": "Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement",
    "summary": "Immunovant shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential best-in-class IgG reductions. Read the latest analysis on the stock here.",
    "url": "https://finnhub.io/api/news?id=91382a859e1d6198bc0dc2b85caa92f01e5c07d55b1436c4ce3927bf65a8e936",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765556911,
      "headline": "Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement",
      "id": 137771727,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2242933015/image_2242933015.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Immunovant shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential best-in-class IgG reductions. Read the latest analysis on the stock here.",
      "url": "https://finnhub.io/api/news?id=91382a859e1d6198bc0dc2b85caa92f01e5c07d55b1436c4ce3927bf65a8e936"
    }
  },
  {
    "ts": null,
    "headline": "Is J&J’s 45.8% 2025 Surge Justified by Its Cash Flow and Earnings Outlook?",
    "summary": "Wondering if Johnson & Johnson is still a steady blue chip or a quietly undervalued opportunity? Let us unpack what the current share price really implies about its long term value. After drifting for a while, J&J has pushed higher recently, with the stock up 3.7% over the last week, 8.3% over the past month, and an impressive 45.8% year to date, translating into a 48.0% gain over the last year. Those kinds of moves suggest the market is rethinking its risk and growth narrative for this...",
    "url": "https://finnhub.io/api/news?id=1f0f29d8a7ff4c0306e78fc2efc98da4825eb099e7ba4255ca374ffb162539e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765548878,
      "headline": "Is J&J’s 45.8% 2025 Surge Justified by Its Cash Flow and Earnings Outlook?",
      "id": 137769297,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Wondering if Johnson & Johnson is still a steady blue chip or a quietly undervalued opportunity? Let us unpack what the current share price really implies about its long term value. After drifting for a while, J&J has pushed higher recently, with the stock up 3.7% over the last week, 8.3% over the past month, and an impressive 45.8% year to date, translating into a 48.0% gain over the last year. Those kinds of moves suggest the market is rethinking its risk and growth narrative for this...",
      "url": "https://finnhub.io/api/news?id=1f0f29d8a7ff4c0306e78fc2efc98da4825eb099e7ba4255ca374ffb162539e9"
    }
  },
  {
    "ts": null,
    "headline": "Proven Income Generators: Ranking the Most Reliable Dividend Growth Stocks",
    "summary": "Dividend investing rewards patience. The best dividend stocks don’t just pay consistently—they raise payouts year after year, compounding income for shareholders who stay the course. Among thousands of publicly traded companies, only a select few have proven they can grow dividends through recessions, market crashes, and industry upheaval. We ranked these six proven dividend winners ... Proven Income Generators: Ranking the Most Reliable Dividend Growth Stocks",
    "url": "https://finnhub.io/api/news?id=5f53f39fd1b331c473e702d6702204cfb9e2cbe8bf567fed0514be7a8ac1608b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765545760,
      "headline": "Proven Income Generators: Ranking the Most Reliable Dividend Growth Stocks",
      "id": 137769299,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Dividend investing rewards patience. The best dividend stocks don’t just pay consistently—they raise payouts year after year, compounding income for shareholders who stay the course. Among thousands of publicly traded companies, only a select few have proven they can grow dividends through recessions, market crashes, and industry upheaval. We ranked these six proven dividend winners ... Proven Income Generators: Ranking the Most Reliable Dividend Growth Stocks",
      "url": "https://finnhub.io/api/news?id=5f53f39fd1b331c473e702d6702204cfb9e2cbe8bf567fed0514be7a8ac1608b"
    }
  },
  {
    "ts": null,
    "headline": "Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis",
    "summary": "AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.",
    "url": "https://finnhub.io/api/news?id=248460a2eebe7df6576d25fbb647abb238f6008f7add18806728bea02d00bc18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765545720,
      "headline": "Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis",
      "id": 137769300,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.",
      "url": "https://finnhub.io/api/news?id=248460a2eebe7df6576d25fbb647abb238f6008f7add18806728bea02d00bc18"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Slipped Below 50-Day SMA Last Week: How to Play the Stock",
    "summary": "AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.",
    "url": "https://finnhub.io/api/news?id=a0611ee8f2fae54ea2e1e0c86e885f7f72f86bdab0218bfc361e63d6342dbd0c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765543320,
      "headline": "AbbVie Slipped Below 50-Day SMA Last Week: How to Play the Stock",
      "id": 137769283,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.",
      "url": "https://finnhub.io/api/news?id=a0611ee8f2fae54ea2e1e0c86e885f7f72f86bdab0218bfc361e63d6342dbd0c"
    }
  },
  {
    "ts": null,
    "headline": "Citigroup Maintains Johnson & Johnson (JNJ) Buy Recommendation",
    "summary": "Citigroup Maintains Johnson & Johnson (JNJ) Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=b1593bd2ada6d218df6d332188edeb92774f52d8088c3941b7798c1d5d527f0f",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765541025,
      "headline": "Citigroup Maintains Johnson & Johnson (JNJ) Buy Recommendation",
      "id": 137766604,
      "image": "",
      "related": "JNJ",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b1593bd2ada6d218df6d332188edeb92774f52d8088c3941b7798c1d5d527f0f"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Maintains Johnson & Johnson (JNJ) Outperform Recommendation",
    "summary": "RBC Capital Maintains Johnson & Johnson (JNJ) Outperform Recommendation",
    "url": "https://finnhub.io/api/news?id=329875f2a7dd07d9a679089a8ac2d5043855a0963a827d631e9a067f4c189eb4",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765497828,
      "headline": "RBC Capital Maintains Johnson & Johnson (JNJ) Outperform Recommendation",
      "id": 137763234,
      "image": "",
      "related": "JNJ",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=329875f2a7dd07d9a679089a8ac2d5043855a0963a827d631e9a067f4c189eb4"
    }
  }
]